't zal maar gebeuren schreef op 9 november 2015 14:47:
By Lauren Pollock
Valeant Pharmaceuticals International Inc. said it would provide a business update during a conference call on Tuesday morning.
The pharmaceutical company's shares have tumbled in recent weeks amid questions about its drug pricing, business and accounting practices. The company has said it has found no evidence of illegality but established a board committee to look into its relationship with a specialty pharmacy that distributed its drugs.
Chief Executive J. Michael Pearson, along with Chief Financial Officer Robert Rosiello and other executives, will take part in the call at 8 a.m. ET.
The company plans to offer an overview of current plans and priorities, including the transition plan from specialty pharmacy Philidor. There will also be a question and answer segment for investors and analysts.
Valeant has previously said Mr. Pearson has the full confidence of its board. William Ackman, one of Valeant's largest shareholders, has also expressed faith in Mr. Pearson but said last week that the board has assured him it is considering any and all alternatives that would benefit shareholders, which could be viewed as an indication the CEO should be prepared to step down or sell the company if more extreme steps become necessary.
Valeant added it intends to host an investor day and update its annual and quarterly financial guidance before the end of the year.
Write to Lauren Pollock at
lauren.pollock@wsj.comSubscribe to WSJ:
online.wsj.com?mod=djnwires(END) Dow Jones Newswires
November 09, 2015 08:37 ET (13:37 GMT)
© 2015 Dow Jones & Company, Inc.
AAND VALEANT PHARMA INTERN AM NOT
CA91911K1021